ASCO 2013

Researchers Discuss Evolution of Immunotherapy Approaches for Gynecologic Malignancies

Researchers Discuss Evolution of Immunotherapy Approaches for Gynecologic Malignancies

By

Immunotherapy approaches are evolving for all types of gynecologic malignancies, including ovarian, cervical, and endometrial cancers.

Pazopanib Maintenance Therapy Delays Relapse in Advanced Ovarian Cancer

By

Maintenance therapy with pazopanib after successful initial chemotherapy for advanced ovarian cancer prolongs time to relapse and PFS compared to placebo, found research presented at ASCO 2013.

Adjuvant Bevacizumab Well-Tolerated in Patients with Melanoma at High Risk of Recurrence

By

In patients with melaoma at high risk of recurrence, adjuvant bevacizumab is well tolerated and improves the disease-free interval, found research presented at ASCO 2013.

No Increased Cardiac Toxicity with Dual HER2 Blockade Therapy for Breast Cancer

By

Combined anti-HER2 therapy, with or without chemotherapy, does not increase the risk for cardiac toxicities compared to anti-HER2 monotherapy, found research presented at ASCO 2013.

Chemotherapy Drug Shortages Affect Patient Care, Impact Clinical Trials

By

A survey found that 83% of U.S. oncologists/hematologists reported a chemo drug shortage in the past 6 months, with 94% stating patient care was affected, according to data presented at ASCO 2013.

ADT Can Be Safely Reduced to 18 Months in Patients with Localized High-Risk Prostate Cancer

By

In men with localized high-risk prostate cancer, androgen-deprivation therapy can be safely reduced from 36 to 18 months, according to research presented at ASCO 2013.

Statins plus Aspirin Improve Overall Survival in Uterine Malignancies

By

Women with uterine malignancies who took statins and aspirin had an 84% reduction in mortality, while use of statins alone reduced mortality by 45%, according to data presented at ASCO 2013.

Anti-PD-L1 Agent Induces Durable Responses in Several Advanced Cancer Tumor Types

By

MPDL3280A produced durable responses in patients with locally advanced or metastatic lung cancer, melanoma, and renal, colorectal, and gastric cancers, some within days of treatment initiation, found research at ASCO 2013.

Nintedanib plus Docetaxel Prolongs PFS in Patients with Metastatic NSCLC

By

Nintedanib in combination with docetaxel significantly prolonged PFS for patients with metastatic NSCLC progressing after first-line chemotherapy regardless of histology, results from the LUME-Lung 1 trial presented at ASCO 2013 have found.

Number of Breast Cancer Gene Alterations Predicts Everolimus Benefit

By

The number of genetic alterations in tumors may predict which patients with breast cancer will benefit from adding everolimus to exemestane, found research presented at ASCO 2013.

VeriStrat 'Clinically Useful to Guide Treatment' in Advanced Lung Cancer

By

VeriStrat test status predicts which patients will see survival benefits from second-line chemotherapy instead of erlotinib therapy for advanced NSCLC, found data presented at ASCO 2013.

Standard-dose RT Superior to High-dose in Patients with Stage III NSCLC Undergoing Chemo

By

Standard-dose radiation therapy is superior to high-dose RT in terms of OS and local-regional control in patients undergoing chemotherapy for stage III NSCLC, found research presented at ASCO 2013.

Imatinib Rechallenge Prolongs PFS but not Overall Survival in Advanced GIST

By

Imatinib is prolongs PFS but not OS compared to placebo among patients with imatinib- or sunitinib-refractory advanced GIST, according to data presented at ASCO 2013.

New PI3K-delta Inhibitor Shows Early Promise for High-risk CLL

By

Idelalisib (GS-1101) is associated with rapid tumor response in some patients diagnosed with relapsed or treatment-resistant CLL, found research presented at ASCO 2013.

Poorer Outcomes Observed for Elderly vs Younger Patients with Metastatic Pancreatic Cancer

By

Elderly patients with metastatic pancreatic cancer have shorter OS and receive less chemotherapy, fewer agents compared to younger patients, found research presented at ASCO 2013.

Next Generation DNA Sequencing Promising in Identifying Targets for Personalized Treatments

By

NGS shows promise in identifying solid tumors harboring "actionable" genetic alterations that can be targeted for personalized therapy, according to study results presented at ASCO 2013.

Sequential Paclitaxel/S-1 Effective Adjuvant in Locally Advanced Gastric Cancer

By

Use of sequential paclitaxel followed by oral fluorinated pyrimidines results in a trend for better disease-free survival in locally advanced gastric cancer, found research presented at ASCO 2013.

African-American Women with Breast Cancer Need Access to More Genetic Counseling, Testing Services

By

African-American women have a high number of breast cancer-related gene mutations and require more access to screening, found results of a study presented at ASCO 2013.

Zoledronic Acid, Sr89 Do Not Prolong Overall Survival in Refractory Prostate Cancer

By

Neither zoledronic acid nor strontium-89 improve OS among patients with castrate-refractory prostate cancer, but Sr89 improves cPFS, according to data presented at ASCO 2013.

Crizotinib Superior to Chemo in Treating ALK-Positive Lung Cancer

Crizotinib Superior to Chemo in Treating ALK-Positive Lung Cancer

For patients with chromosomal rearrangements of the of the ALK gene, crizotinib yields longer PFS and a higher response rate versus standard chemotherapy, found data presented at ASCO 2013.

Case of Acquired Resistance to Crizotinib Described

Case of Acquired Resistance to Crizotinib Described

A case of acquired resistance to crizotinib has been described in a patient with metastatic lung adenocarcinoma harboring a CD74-ROS1 rearrangement, according to research presented at ASCO 2013.

New Chaperone-Targeting Ganetespib Prolongs Survival in Advanced Lung Cancer

By

Adding ganetespib to docetaxel in salvage therapy prolongs OS compared to docetaxel alone among patients diagnosed with advanced adenocarcinoma lung cancer, research presented at ASCO 2013 has found.

Weekly Adjuvant Paclitaxel Offers Lower Post-Surgical Toxicity in Early-Stage Breast Cancer

By

Low-dose weekly paclitaxel and standard every-other-week paclitaxel dosing offer equivalent postsurgical PFS rates among women with higher-risk early-stage breast cancer, according to research presented at ASCO 2013.

Vinegar-Based Screenings Reduce Cervical Cancer Mortality by 31% Over 15 Years

By

Simple vinegar-based visual inspection screenings by primary paramedical health workers reduced cervical cancer mortality by 31% over 15 years, research presented at ASCO 2013 has found.

No Equivalence for Paclitaxel vs Doxorubicin/Cyclophosphamide as Adjuvant Treatment for Breast Cancer

By

Single-agent paclitaxel did not show equivalence to doxorubicin and cyclophosphamide as adjuvant therapy for breast cancer in women with zero to three axillary nodes, found data presented at ASCO 2013.

Bevacizumab Does Not Improve Survival in Newly-Diagnosed Glioblastoma

By

Among patients with newly-diagnosed glioblastoma, adding bevacizumab to standard first-line chemoradiotherapy does not improve survival, found data presented at ASCO 2013.

RT Offers Less Lymphedema, Comparable Breast Cancer Recurrence vs ALN Dissection

By

Axillary radiotherapy offers 5-year survival rates comparable to surgical dissection of the axillary lymph nodes, and a lower risk of lymphedema, according to research presented at ASCO 2013.

Continuing Tamoxifen to 10 Years Produces Further Reductions in Breast Cancer Recurrence, Death

By

Continuing adjuvant tamoxifen beyond 5 years in ER+ disease reduces breast cancer recurrence, with benefit occurring primarily after year 7, found research presented at ASCO 2013.

Bevacizumab plus Chemotherapy Extends Survival in Recurrent or Persistent Stage IVB Cervical Carcinoma

By

Bevacizumab extended survival in women with relapsed/advanced cervical cancer, the first time a targeted agent has significantly improved OS in gynecologic cancer, according to data presented at ASCO 2013.

Sorafenib Improves Progression-free Survival in Radioactive Iodine-refractory Metastatic Differentiated Thyroid Cancer

By

Sorafenib represents a potential new treatment option for patients with locally advanced or metastatic RAI-refractory differentiated thyroid cancer, according to research presented at ASCO 2013.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs